A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Clinical trial NCT05103917 · UNKNOWN

Trial details

NCT number: NCT05103917
Sponsor: Abbisko Therapeutics Co, Ltd
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2021-07-21
Primary completion: 2022-11-24
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.